| scholarly article | Q13442814 |
| P50 | author | Ruth Nussinov | Q7383152 |
| Chung-Jung Tsai | Q57578576 | ||
| P2093 | author name string | Peter Csermely | |
| P2860 | cites work | Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation | Q24554295 |
| The implications of human metabolic network topology for disease comorbidity | Q24655183 | ||
| DNA Binding Site Sequence Directs Glucocorticoid Receptor Structure and Activity | Q27654868 | ||
| RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer | Q27657185 | ||
| Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety | Q27658795 | ||
| An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase | Q27662837 | ||
| Crystal Structure of UBA2ufd-Ubc9: Insights into E1-E2 Interactions in Sumo Pathways | Q27666500 | ||
| Multimeric assembly and biochemical characterization of the Trax–translin endonuclease complex | Q27667762 | ||
| Enzyme Inhibition by Allosteric Capture of an Inactive Conformation | Q27670647 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Network biology: understanding the cell's functional organization | Q27861027 | ||
| Structure and TBP binding of the Mediator head subcomplex Med8-Med18-Med20. | Q27936384 | ||
| The enhanceosome | Q28265371 | ||
| The human Mediator complex: a versatile, genome-wide regulator of transcription | Q28276700 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| Systems biology: a brief overview | Q29547514 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Disordered proteins and network disorder in network descriptions of protein structure, dynamics and function: hypotheses and a comprehensive review | Q30408830 | ||
| Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology | Q30479035 | ||
| mTOR and cancer: many loops in one pathway. | Q33348248 | ||
| Evolution-guided discovery and recoding of allosteric pathway specificity determinants in psychoactive bioamine receptors | Q33348925 | ||
| Allostery and population shift in drug discovery | Q37795355 | ||
| "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology | Q37845809 | ||
| Specific Gene Signatures and Pathways in Mesodermal Cells and Their Derivatives Derived from Embryonic Stem Cells | Q37868975 | ||
| The transcriptional and signalling networks of pluripotency | Q37871828 | ||
| Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation | Q39528587 | ||
| Structure of the human mTOR complex I and its implications for rapamycin inhibition. | Q39694102 | ||
| Network-based tools for the identification of novel drug targets. | Q39749340 | ||
| Inhibitor hijacking of Akt activation | Q39847621 | ||
| Transient non-native hydrogen bonds promote activation of a signaling protein | Q41389114 | ||
| p53 activates transcription by directing structural shifts in Mediator | Q41824511 | ||
| Edgetic perturbation models of human inherited disorders | Q42124353 | ||
| PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. | Q45998535 | ||
| Controllability of complex networks | Q51569838 | ||
| Analytical pharmacology: the impact of numbers on pharmacology | Q83597766 | ||
| Malleable machines in transcription regulation: the mediator complex | Q33394559 | ||
| Trapping moving targets with small molecules | Q33428910 | ||
| The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update | Q33533858 | ||
| Small molecule probes of cellular pathways and networks | Q33750619 | ||
| Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery | Q33890786 | ||
| Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms | Q33968222 | ||
| Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. | Q34064787 | ||
| Allosteric Suppression of HIV-1 Reverse Transcriptase Structural Dynamics upon Inhibitor Binding | Q34439424 | ||
| Induced fit, conformational selection and independent dynamic segments: an extended view of binding events | Q34479883 | ||
| Structural assembly of cullin-RING ubiquitin ligase complexes | Q34762436 | ||
| MultiBind and MAPPIS: webservers for multiple alignment of protein 3D-binding sites and their interactions | Q34777516 | ||
| A Rit GTPase-p38 Mitogen-Activated Protein Kinase Survival Pathway Confers Resistance to Cellular Stress | Q35096530 | ||
| Is allostery an intrinsic property of all dynamic proteins? | Q35894622 | ||
| The efficiency of multi-target drugs: the network approach might help drug design | Q36088532 | ||
| Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. | Q36212551 | ||
| The changing landscape of protein allostery | Q36372723 | ||
| Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design | Q36458965 | ||
| Perturbations to uncover gene networks | Q36650695 | ||
| Comparative genomics supports a deep evolutionary origin for the large, four-module transcriptional mediator complex | Q36777813 | ||
| Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α | Q36926447 | ||
| Acquired resistance to tyrosine kinase inhibitors during cancer therapy | Q37104243 | ||
| Allostery: absence of a change in shape does not imply that allostery is not at play | Q37114191 | ||
| Amplification of signaling via cellular allosteric relay and protein disorder | Q37182653 | ||
| PRISM: protein-protein interaction prediction by structural matching | Q37200809 | ||
| Genomic analysis reveals a tight link between transcription factor dynamics and regulatory network architecture | Q37330215 | ||
| The origin of allosteric functional modulation: multiple pre-existing pathways | Q37359180 | ||
| Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders | Q37360436 | ||
| Perturbation waves in proteins and protein networks: applications of percolation and game theories in signaling and drug design. | Q37438478 | ||
| '7TM receptor allostery: putting numbers to shapeshifting proteins | Q37591623 | ||
| Prion protein and Alzheimer disease | Q37627085 | ||
| Dissecting the role of mTOR: lessons from mTOR inhibitors | Q37652233 | ||
| Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery. | Q37764610 | ||
| Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs | Q37784750 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 686-693 | |
| P577 | publication date | 2011-09-16 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Allo-network drugs: harnessing allostery in cellular networks | |
| P478 | volume | 32 |
| Q27684011 | A Mechanism for the Auto-inhibition of Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) Channel Opening and Its Relief by cAMP |
| Q41035952 | A Panel of TrpB Biocatalysts Derived from Tryptophan Synthase through the Transfer of Mutations that Mimic Allosteric Activation |
| Q37661864 | ASD v2.0: updated content and novel features focusing on allosteric regulation |
| Q40069576 | Alloscore: a method for predicting allosteric ligand-protein interactions |
| Q43492056 | Allosite: a method for predicting allosteric sites |
| Q92490605 | Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders |
| Q35981965 | Allosteric Partial Inhibition of Monomeric Proteases. Sulfated Coumarins Induce Regulation, not just Inhibition, of Thrombin. |
| Q38134781 | Allosteric conformational barcodes direct signaling in the cell |
| Q36147266 | Allosteric modulators can restore function in an amino acid neurotransmitter receptor by slightly altering intra‐molecular communication pathways |
| Q37220392 | Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks |
| Q38817910 | Allosteric modulators of MEK1: drug design and discovery |
| Q30352755 | An automated approach to network features of protein structure ensembles |
| Q47572067 | Attractor Structures of Signaling Networks: Consequences of Different Conformational Barcode Dynamics and Their Relations to Network-Based Drug Design |
| Q91889015 | Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention |
| Q26738619 | Biophysical and computational methods to analyze amino acid interaction networks in proteins |
| Q64233001 | CASBench: A Benchmarking Set of Proteins with Annotated Catalytic and Allosteric Sites in Their Structures |
| Q44428862 | Cancer-related networks: A help to understand, predict and change malignant transformation |
| Q41668268 | Computational and experimental analyses reveal the essential roles of interdomain linkers in the biological function of chemotaxis histidine kinase CheA. |
| Q90047400 | Conformational Dynamics and Allosteric Regulation Landscapes of Germline PTEN Mutations Associated with Autism Compared to Those Associated with Cancer |
| Q36764852 | Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell |
| Q91675504 | Does Ras Activate Raf and PI3K Allosterically? |
| Q30358225 | Emerging Computational Methods for the Rational Discovery of Allosteric Drugs. |
| Q47565712 | Energetic redistribution in allostery to execute protein function |
| Q50917562 | Evolution of the concept of conformational dynamics of enzyme functions over half of a century: A personal view |
| Q30422757 | Exploiting protein flexibility to predict the location of allosteric sites |
| Q83794016 | Finding Hsp90 inhibitors by drug repurposing: The power of chemical genetics |
| Q28969528 | Harnessing Big Data for Systems Pharmacology |
| Q30429074 | High quality drug screening by capillary electrophoresis: A review |
| Q42083172 | How an Inhibitor Bound to Subunit Interface Alters Triosephosphate Isomerase Dynamics |
| Q37475825 | Identification of critical paralog groups with indispensable roles in the regulation of signaling flow |
| Q89510669 | Integrated Computational Approaches and Tools forAllosteric Drug Discovery |
| Q42043842 | Model for high-throughput screening of multitarget drugs in chemical neurosciences: synthesis, assay, and theoretic study of rasagiline carbamates. |
| Q38017212 | Modular pharmacology: the next paradigm in drug discovery |
| Q44930444 | Multi-targeted therapy for leprosy: Insilico strategy to overcome multi drug resistance and to improve therapeutic efficacy |
| Q38163208 | Multiple conformational selection and induced fit events take place in allosteric propagation. |
| Q34790185 | Multiscale modeling of the causal functional roles of nsSNPs in a genome-wide association study: application to hypoxia |
| Q92148966 | NAPS update: network analysis of molecular dynamics data and protein-nucleic acid complexes |
| Q28534547 | Perturbation centrality and turbine: a novel centrality measure obtained using a versatile network dynamics tool |
| Q64259068 | Precision medicine review: rare driver mutations and their biophysical classification |
| Q44697358 | Prediction of allosteric sites on protein surfaces with an elastic-network-model-based thermodynamic method |
| Q26996431 | Principles of allosteric interactions in cell signaling |
| Q31039692 | Protein Ensembles: How Does Nature Harness Thermodynamic Fluctuations for Life? The Diverse Functional Roles of Conformational Ensembles in the Cell |
| Q64967550 | Protein ensembles link genotype to phenotype. |
| Q28552402 | Quantitative Determination of Flexible Pharmacological Mechanisms Based On Topological Variation in Mice Anti-Ischemic Modular Networks |
| Q92442397 | Resolution of Complex Issues in Genome Regulation and Cancer Requires Non-Linear and Network-Based Thermodynamics |
| Q62648881 | Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers |
| Q28708808 | Self-organization of progress across the century of physics |
| Q34256222 | Short Co-occurring Polypeptide Regions Can Predict Global Protein Interaction Maps. |
| Q34554087 | SignaLink 2 - a signaling pathway resource with multi-layered regulatory networks |
| Q38109305 | Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development |
| Q27008867 | Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review |
| Q36949884 | Structure-based network analysis of an evolved G protein-coupled receptor homodimer interface. |
| Q99417557 | Supertertiary protein structure affects an allosteric network |
| Q40513256 | Targets of drugs are generally, and targets of drugs having side effects are specifically good spreaders of human interactome perturbations |
| Q34334937 | Tertiary and quaternary effects in the allosteric regulation of animal hemoglobins |
| Q47576030 | The NRF2-related interactome and regulome contain multifunctional proteins and fine-tuned autoregulatory loops. |
| Q47577552 | The different ways through which specificity works in orthosteric and allosteric drugs |
| Q36721779 | The role of allostery in the ubiquitin-proteasome system |
| Q34365654 | The structural basis for cancer treatment decisions |
| Q30427743 | The underappreciated role of allostery in the cellular network. |
| Q38125039 | Towards a detailed atlas of protein–protein interactions |
| Q28538838 | Towards structural systems pharmacology to study complex diseases and personalized medicine |
| Q36641099 | Vitexicarpin Acts as a Novel Angiogenesis Inhibitor and Its Target Network |
Search more.